Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-Adapted Chemotherapy for Non-Bulky Stage I and II Hodgkin Lymphoma
NCT01132807Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2010
- Primary completion
- Feb 2016
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, bleomycin, vinblastine, dacarbazine in Hodgkin lymphoma (HL), sponsored by Cancer and Leukemia Group B. Started May 2010; status: completed.
02
Drugs
pegylated liposomal doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01132807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132807.